vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Dayforce (DAY). Click either name above to swap in a different company.
Dayforce is the larger business by last-quarter revenue ($481.6M vs $284.0M, roughly 1.7× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -40.9%, a 137.2% gap on every dollar of revenue. On growth, Dayforce posted the faster year-over-year revenue change (9.5% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 9.8%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Dayforce, Inc., formerly Ceridian, is an American human resources software and services company.
ACAD vs DAY — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $481.6M |
| Net Profit | $273.6M | $-196.8M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 6.3% |
| Net Margin | 96.3% | -40.9% |
| Revenue YoY | 9.4% | 9.5% |
| Net Profit YoY | 90.3% | -9940.0% |
| EPS (diluted) | $1.61 | $-1.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | — | ||
| Q3 25 | $278.6M | $481.6M | ||
| Q2 25 | $264.6M | $464.7M | ||
| Q1 25 | $244.3M | $481.8M | ||
| Q4 24 | $259.6M | $465.2M | ||
| Q3 24 | $250.4M | $440.0M | ||
| Q2 24 | $242.0M | $423.3M | ||
| Q1 24 | $205.8M | $431.5M |
| Q4 25 | $273.6M | — | ||
| Q3 25 | $71.8M | $-196.8M | ||
| Q2 25 | $26.7M | $21.3M | ||
| Q1 25 | $19.0M | $14.9M | ||
| Q4 24 | $143.7M | $10.8M | ||
| Q3 24 | $32.8M | $2.0M | ||
| Q2 24 | $33.4M | $-1.8M | ||
| Q1 24 | $16.6M | $7.1M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | 47.0% | ||
| Q3 24 | 92.5% | 45.8% | ||
| Q2 24 | 92.5% | 44.1% | ||
| Q1 24 | 88.8% | 47.6% |
| Q4 25 | 6.1% | — | ||
| Q3 25 | 12.8% | 6.3% | ||
| Q2 25 | 12.2% | 9.1% | ||
| Q1 25 | 7.9% | 6.4% | ||
| Q4 24 | 59.1% | 6.1% | ||
| Q3 24 | 12.6% | 4.7% | ||
| Q2 24 | 12.6% | 3.3% | ||
| Q1 24 | 7.4% | 9.4% |
| Q4 25 | 96.3% | — | ||
| Q3 25 | 25.8% | -40.9% | ||
| Q2 25 | 10.1% | 4.6% | ||
| Q1 25 | 7.8% | 3.1% | ||
| Q4 24 | 55.4% | 2.3% | ||
| Q3 24 | 13.1% | 0.5% | ||
| Q2 24 | 13.8% | -0.4% | ||
| Q1 24 | 8.0% | 1.6% |
| Q4 25 | $1.61 | — | ||
| Q3 25 | $0.42 | $-1.23 | ||
| Q2 25 | $0.16 | $0.13 | ||
| Q1 25 | $0.11 | $0.09 | ||
| Q4 24 | $0.86 | $0.07 | ||
| Q3 24 | $0.20 | $0.01 | ||
| Q2 24 | $0.20 | $-0.01 | ||
| Q1 24 | $0.10 | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $627.6M |
| Total DebtLower is stronger | — | $631.1M |
| Stockholders' EquityBook value | $1.2B | $2.7B |
| Total Assets | $1.6B | $8.7B |
| Debt / EquityLower = less leverage | — | 0.23× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | — | ||
| Q3 25 | $258.0M | $627.6M | ||
| Q2 25 | $253.6M | $625.2M | ||
| Q1 25 | $217.7M | $557.3M | ||
| Q4 24 | $319.6M | $579.7M | ||
| Q3 24 | $155.1M | $494.1M | ||
| Q2 24 | $177.1M | $465.4M | ||
| Q1 24 | $204.7M | $392.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $631.1M | ||
| Q2 25 | — | $631.8M | ||
| Q1 25 | — | $632.4M | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $917.3M | $2.7B | ||
| Q2 25 | $822.4M | $2.7B | ||
| Q1 25 | $765.2M | $2.6B | ||
| Q4 24 | $732.8M | $2.5B | ||
| Q3 24 | $577.2M | $2.6B | ||
| Q2 24 | $516.7M | $2.5B | ||
| Q1 24 | $464.0M | $2.4B |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.3B | $8.7B | ||
| Q2 25 | $1.2B | $8.5B | ||
| Q1 25 | $1.1B | $9.5B | ||
| Q4 24 | $1.2B | $9.1B | ||
| Q3 24 | $976.9M | $8.1B | ||
| Q2 24 | $914.1M | $9.0B | ||
| Q1 24 | $855.1M | $10.8B |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | — | 0.23× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.47× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | 0.50× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $31.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | — | ||
| Q3 25 | $74.3M | $31.2M | ||
| Q2 25 | $64.0M | $112.7M | ||
| Q1 25 | $20.3M | $49.6M | ||
| Q4 24 | $40.4M | $81.0M | ||
| Q3 24 | $63.2M | $91.8M | ||
| Q2 24 | $25.0M | $99.2M | ||
| Q1 24 | $29.1M | $9.1M |
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | 5.29× | ||
| Q1 25 | 1.07× | 3.33× | ||
| Q4 24 | 0.28× | 7.50× | ||
| Q3 24 | 1.93× | 45.90× | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | 1.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
DAY
| Dayforce Recurring | $333.0M | 69% |
| Cloud And Bureau Professional Services And Other | $78.5M | 16% |
| Float | $42.2M | 9% |
| Powerpay Recurring | $19.7M | 4% |
| Other Recurring | $8.2M | 2% |
